Cargando…

A Case of CCDC6-RET Fusion Mutation in Adult Acute Lymphoblastic Leukemia (ALL), a Known Activating Mutation Reported in ALL

We report the case of a patient with B-Cell Acute Lymphoblastic Leukemia (ALL) who was found to harbor a gene fusion involving the CCDC6 and RET genes. Although the RET mutations have been identified before in other malignancies, and it is thought to represent a driver mutation in these neoplasms, i...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mejia Saldarriaga, Mateo, Steinberg, Amir, Severson, Eric A., Binder, Adam
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2019
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6901674/ https://www.ncbi.nlm.nih.gov/pubmed/31850206 http://dx.doi.org/10.3389/fonc.2019.01303

Ejemplares similares

Response to Pralsetinib in Multi-Drug-Resistant Breast Cancer With CCDC6-RET Mutation
por: Zhao, Jing, et al.
Publicado: (2023)

Use of Cabozantinib in a Patient With EGFR-Mutated Non–Small-Cell Lung Cancer Harboring Acquired CCDC6-RET Fusion
por: Chae, Young Kwang, et al.
Publicado: (2019)

Prognostic significance of steroid response in pediatric acute lymphoblastic leukemia: The CCCG-ALL-2015 study
por: Chu, Jinhua, et al.
Publicado: (2022)

EGF Induced RET Inhibitor Resistance in CCDC6-RET Lung Cancer Cells
por: Chang, Hyun, et al.
Publicado: (2017)

RET fusion mutation detected by re-biopsy 7 years after initial cytotoxic chemotherapy: A case report
por: Morikawa, Kei, et al.
Publicado: (2022)

Cardiac ALL: Most Unusual Occurrence of Lenalidomide-associated Acute Lymphoblastic Leukemia with Subsequent Cardiac Involvement
por: Sharma, Naman, et al.
Publicado: (2019)

A Novel Risk Defining System for Pediatric T-Cell Acute Lymphoblastic Leukemia From CCCG-ALL-2015 Group
por: Liu, Xiaoming, et al.
Publicado: (2022)

Pericardial Relapse of Acute Lymphoblastic Leukemia (ALL)
por: Maslov, Diana V., et al.
Publicado: (2021)

The Addition of All-Trans Retinoic Acid to Chemotherapy May Not Improve the Outcome of Patient with NPM1 Mutated Acute Myeloid Leukemia
por: Nazha, Aziz, et al.
Publicado: (2013)

Inhibition of FGF receptor blocks adaptive resistance to RET inhibition in CCDC6-RET–rearranged thyroid cancer
por: Raman, Renuka, et al.
Publicado: (2022)

Emerging Necessity of Myeloid Mutational Analysis in Early T-cell Precursor Acute Lymphoblastic Leukemia/Lymphoma (ETP-ALL)
por: Tariq, Hamza, et al.
Publicado: (2023)

Targeted Therapy for RET Fusion Lung Cancer: Breakthrough and Unresolved Issue
por: Takamori, Shinkichi, et al.
Publicado: (2021)

Research Progress on RET Fusion in Non-Small-Cell Lung Cancer
por: Zhao, Lu, et al.
Publicado: (2022)

The Treatment Status of Patients in NSCLC With RET Fusion Under the Prelude of Selective RET-TKI Application in China: A Multicenter Retrospective Research
por: Meng, Yan, et al.
Publicado: (2022)

Pralsetinib for the treatment of a RET-positive advanced non-small-cell lung cancer patient harboring both ANK-RET and CCDC6-RET fusions with coronary heart disease: a case report
por: Meng, Yan, et al.
Publicado: (2022)

Durable response to low-dose pralsetinib in a renal insufficient patient with NSCLC harboring concurrent CCDC6-RET, LINCO1264-RET, and SEMA5A-RET fusions: A case report
por: Gu, Linping, et al.
Publicado: (2022)

Sensitivity to Pain in Children With Acute Lymphoblastic Leukemia (ALL)
por: Firoozi, Manijeh, et al.
Publicado: (2012)

ACUTE Lymphoblastic Leukemia (ALL) and COVID-19 Infection. a Campus ALL Report
por: Chiaretti, Sabina, et al.
Publicado: (2021)

RET signaling pathway and RET inhibitors in human cancer
por: Regua, Angelina T., et al.
Publicado: (2022)

Targeted therapy in NPM1-mutated AML: Knowns and unknowns
por: Wang, Rong, et al.
Publicado: (2022)

Characteristics of T-Cell Receptor Repertoire and Correlation With EGFR Mutations in All Stages of Lung Cancer
por: Yang, Huaxia, et al.
Publicado: (2021)

Targeted therapy of RET fusion-positive non-small cell lung cancer
por: Shen, Zixiong, et al.
Publicado: (2022)

Delineation of CCDC39/CCDC40 mutation spectrum and associated phenotypes in primary ciliary dyskinesia
por: Legendre, M, et al.
Publicado: (2012)

Case Report: A novel intergenic MIR4299/MIR8070-RET fusion with RET amplification and clinical response to pralsetinib in a lung adenocarcinoma patient
por: Wang, Sha-Sha, et al.
Publicado: (2022)

Latest Contributions of Genomics to T-Cell Acute Lymphoblastic Leukemia (T-ALL)
por: Genescà, Eulàlia, et al.
Publicado: (2022)

Changing Landscape in the Treatment of Adult Acute Lymphoblastic Leukemia (ALL)
por: Künz, Tina, et al.
Publicado: (2022)

Corrigendum: Case report: A novel intergenic MIR4299/MIR8070-RET fusion with RET amplification and clinical response to pralsetinib in a lung adenocarcinoma patient
por: Wang, Sha-Sha, et al.
Publicado: (2022)

Prognostic Significance of Comprehensive Gene Mutations and Clinical Characteristics in Adult T-Cell Acute Lymphoblastic Leukemia Based on Next-Generation Sequencing
por: Yin, Hua, et al.
Publicado: (2022)

Mutations in CCDC39 and CCDC40 are a major cause of primary ciliary dyskinesia with microtubule disorganisation
por: Antony, D, et al.
Publicado: (2012)

Cost-utility of Protocols of BFM-ALL and UK-ALL for Treatment of Children with Acute Lymphoblastic Leukemia in Iran
por: HAYATI, Hadi, et al.
Publicado: (2018)

Whole transcriptome sequencing reveals a TCF4-ZNF384 fusion in acute lymphoblastic leukemia
por: Wu, Zhengyu, et al.
Publicado: (2022)

Leukemia-Initiating Cells in T-Cell Acute Lymphoblastic Leukemia
por: Tan, Shi Hao, et al.
Publicado: (2017)

Selpercatinib and capmatinib combination promotes sustained complete response in novel ISOC1-RET fusion lung cancer after resistance to RET inhibitor via MET amplification: Case Report
por: Leite, Caio Abner, et al.
Publicado: (2023)

RET Solvent Front Mutations Mediate Acquired Resistance to Selective RET Inhibition in RET-Driven Malignancies
por: Solomon, Benjamin J., et al.
Publicado: (2020)

Therapeutic Targeting of c-Myc in T-Cell Acute Lymphoblastic Leukemia (T-ALL)
por: Loosveld, Marie, et al.
Publicado: (2014)

Costs associated with adverse events from remission induction for children with Acute Lymphoblastic Leukemia (ALL)
por: Mejía-Aranguré, Eréndira, et al.
Publicado: (2022)

Rapid Molecular Response to Dasatinib in a Pediatric Relapsed Acute Lymphoblastic Leukemia With NCOR1-LYN Fusion
por: Dai, Hai-Ping, et al.
Publicado: (2020)

Case Report: A novel FGFR1 fusion in acute B-lymphoblastic leukemia identified by RNA sequencing
por: Zhang, Zhibo, et al.
Publicado: (2023)

Multi-Omics Analysis of Acute Lymphoblastic Leukemia Identified the Methylation and Expression Differences Between BCP-ALL and T-ALL
por: Li, Jin-Fan, et al.
Publicado: (2021)

Day 15 and Day 33 Minimal Residual Disease Assessment for Acute Lymphoblastic Leukemia Patients Treated According to the BFM ALL IC 2009 Protocol: Single-Center Experience of 133 Cases
por: Radu, Letitia-Elena, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_kt9p7eu54k45pmt05mopjmsslq